KLRS compared with CHRS: revenue, margins and what each company keeps, and the suppliers and customers both name

KLRSKalaris Therapeutics, Inc.

Mkt capRevenueRevenue

CHRSCoherus Oncology, Inc.

Mkt capRevenueRevenue

Compare

KLRSKalaris Therapeutics, Inc.

CHRSCoherus Oncology, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

KLRS1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+0.76%—

CHRS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±36.1%▼−12.76%×0.35

May 12 '26±12.4%▼−12.31%×0.99

= impliedKLRS realized, solidCHRS realized, hatchedOne scale, both sides: full bar = 37%× = |realized| ÷ impliedSource: market data

Q1 FY26

±34.7%

▲+1.04%

×0.03

Jan 13 '26±20.9%▲+3.03%×0.14

KLRSKalaris Therapeutics, Inc.

2.00· pre 2.06· delayed

Mkt cap$48.3MRevenue—Revenue—

CHRSCoherus Oncology, Inc.

0.87· pre 0.77· delayed

Pre-marketNov 2 '26delayed

Mkt cap$115.8MRevenue$14MQ2 FY26Revenue$42MFY25

Compare

Pre-marketNov 2 '26delayed

KLRSKalaris Therapeutics, Inc.

CHRSCoherus Oncology, Inc.

2.00pre 2.06delayed

Price

0.87pre 0.77delayed

$48.3M

Mkt cap

$115.8M

—

Revenue

$14MQ2 FY26

—

Revenue

$42MFY25

KLRS2.00vsCHRS0.87Pre-marketNov 2 '26delayed